Evidence map›Paper›PMID 38584111›Full record

ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2024

[Liver cancer treatment with mitochondrial homeostasis].

M F Song, L Y Ma, C Shen, Q Zhao, C Y Zhao

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

M F SongDepartment of Infectious Disease, the Third Hospital of Hebei Medical University, Shijiazhuang 050051, China.
L Y MaDepartment of Infectious Disease, the Third Hospital of Hebei Medical University, Shijiazhuang 050051, China.
C ShenDepartment of Infectious Disease, the Third Hospital of Hebei Medical University, Shijiazhuang 050051, China.
Q ZhaoQuality Management and Control Office, the Third Hospital of Hebei Medical University, Shijiazhuang 050051, China.
C Y ZhaoDepartment of Infectious Disease, the Third Hospital of Hebei Medical University, Shijiazhuang 050051, China.

Funding

Innovation Ability Promotion Project of Hebei Infectious Disease Clinical Medical Research Center S&T Program of Hebei, 20577704DNational Natural Science Foundation of China Youth Science Foundation 81900536Project of Precision Medicine Joint Fund Cultivation of Hebei Province H2022206342
6 · The paper itself

Abstract

Systemic treatment, including molecular targeted therapy, immunotherapy, and chemotherapy, is an important means of achieving long-term survival in patients with intermediate-and advanced-stage liver cancer. However, some patients are insensitive to treatment and even develop drug resistance. Mitochondria are the center of cellular energy metabolism and, at the same time, are the priority targets for systemic therapy. Mitochondrial homeostasis plays an important role in the treatment of liver cancer. The relationship between the two advances is elucidated so as to provide better ideas for the clinical treatment of liver cancer.

Indexed as

Liver NeoplasmsMitochondriaHomeostasisHumansImmunotherapyLiver cancerMitochondrial homeostasisSystemic treatment

Identifiers

PMID38584111
PMCPMC12814804

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.